N-BOC 4-(苯基磺酰基)哌啶 | 400729-18-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: N-BOC 4-(苯基磺酰基)哌啶
• 中文别名: N-BOC4-(苯基磺酰基)哌啶
• 英文名称: N-BOC 4-(phenylsulfonyl)piperidine
• 英文别名: tert-butyl 4-(phenylsulfonyl)piperidine-1-carboxylate；tert-butyl 4-(benzenesulfonyl)piperidine-1-carboxylate
• CAS: 400729-18-2
• 化学式: C₁₆H₂₃NO₄S
• 分子量: 325.429
• InChiKey: KOMXHBTWUSKPAQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  22
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  72.1
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  N-BOC 4-(苯基磺酰基)哌啶 在 盐酸 、 potassium carbonate 、 sodium iodide 作用下， 以 甲醇 、 乙腈 为溶剂， 反应 51.0h， 生成 4-(4-Benzenesulfonyl-piperidin-1-yl)-1-(4-fluoro-phenyl)-butan-1-one
  参考文献：
  名称：

  4-(Phenylsulfonyl)piperidines:  Novel, Selective, and Bioavailable 5-HT_2A Receptor Antagonists

  摘要：

  On the basis of a spirocyclic ether screening lead, a series of acyclic sulfones have been identifed as high-affinity, selective 5-HT2A receptor antagonists. Bioavailability lacking in the parent, 1-(2-(2,4-difluorophenyl)ethyl)-4-(phenylsulfonyl)piperidine (12), was introduced by using stability toward rat liver microsomes as a predictor of bioavailability. By this means, the 4-cyano- and 4-carboxamidophenylsulfonyl derivatives 26 and 31 were identified as orally bioavailable, brain-penetrant analogues suitable for evaluation in animal models. Bioavailability was also attainable by N substitution leading to the N-phenacyl derivative 35. IKr activity detected through counterscreening was reduced to insignificant levels in vivo with the latter compound.

  DOI：

  10.1021/jm011030v
• 作为产物：
  描述：

  tert-butyl 4-(phenylthio)piperidine-1-carboxylate 在 间氯过氧苯甲酸 作用下， 以 二氯甲烷 为溶剂， 反应 12.0h， 以604 mg的产率得到N-BOC 4-(苯基磺酰基)哌啶
  参考文献：
  名称：

  碱介导的烷基砜自由基硼化反应

  摘要：

  据报道，在与 B 2 neop 2的碱介导的硼基化反应中，利用失活的烷基砜作为烷基自由基前体，从而无需进一步酯交换即可直接获得有价值的烷基硼酸酯。这种方法具有可扩展性，并且能够耐受各种官能团和底物，包括复杂分子。

  DOI：

  10.1002/chem.202103866

文献信息

• ACETYL COENZYME A CARBOXYLASE INHIBITORS
  申请人：Chang Edcon

  公开号：US20090005375A1

  公开（公告）日：2009-01-01

  The present invention relates to acetyl coenzyme-A carboxylase (“ACC”) inhibiting compounds of the formula wherein the variables are as defined herein. In particular, the present invention relates to ACC1 and/or ACC2 inhibitors, compositions of matter, kits and articles of manufacture comprising these compounds, methods for inhibiting ACC1 and/or ACC2, and methods of making the inhibitors.
• Base‐Mediated Radical Borylation of Alkyl Sulfones
  作者：Mingming Huang、Jiefeng Hu、Ivo Krummenacher、Alexandra Friedrich、Holger Braunschweig、Stephen A. Westcott、Udo Radius、Todd B. Marder

  DOI：10.1002/chem.202103866

  日期：2022.1.13

  The utilization of inactivated alkyl sulfones as alkyl radical precursors in a base-mediated borylation reaction with B2neop2 is reported, allowing direct access to valuable alkyl boronate esters without further transesterification. This approach is scalable and is tolerant to a variety of functional groups and substrates including complex molecules.

  据报道，在与 B 2 neop 2的碱介导的硼基化反应中，利用失活的烷基砜作为烷基自由基前体，从而无需进一步酯交换即可直接获得有价值的烷基硼酸酯。这种方法具有可扩展性，并且能够耐受各种官能团和底物，包括复杂分子。
• 4-(Phenylsulfonyl)piperidines:  Novel, Selective, and Bioavailable 5-HT_2A Receptor Antagonists
  作者：Stephen R. Fletcher、Frank Burkamp、Peter Blurton、Susan K. F. Cheng、Robert Clarkson、Desmond O'Connor、Daniel Spinks、Matthew Tudge、Monique B. van Niel、Smita Patel、Kerry Chapman、Rose Marwood、Sara Shepheard、Graham Bentley、Gina P Cook、Linda J Bristow、Jose L. Castro、Peter H. Hutson、Angus M. MacLeod

  DOI：10.1021/jm011030v

  日期：2002.1.1

  On the basis of a spirocyclic ether screening lead, a series of acyclic sulfones have been identifed as high-affinity, selective 5-HT2A receptor antagonists. Bioavailability lacking in the parent, 1-(2-(2,4-difluorophenyl)ethyl)-4-(phenylsulfonyl)piperidine (12), was introduced by using stability toward rat liver microsomes as a predictor of bioavailability. By this means, the 4-cyano- and 4-carboxamidophenylsulfonyl derivatives 26 and 31 were identified as orally bioavailable, brain-penetrant analogues suitable for evaluation in animal models. Bioavailability was also attainable by N substitution leading to the N-phenacyl derivative 35. IKr activity detected through counterscreening was reduced to insignificant levels in vivo with the latter compound.